Literature DB >> 3021931

Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas.

A K Choucair, V A Levin, P H Gutin, R L Davis, P Silver, M S Edwards, C B Wilson.   

Abstract

To determine the percentage of patients who developed multiple central nervous system (CNS) gliomas during postoperative radiation therapy and chemotherapy, the authors reviewed the records of 1047 patients treated between December 2, 1976, and August 16, 1985, who had an original diagnosis of supratentorial glioblastoma multiforme or other anaplastic glioma. The occurrence of multiple lesions was verified by neurodiagnostic studies (computerized tomography or myelography) or by findings at operation or autopsy. Twelve patients (1.1%) who presented with multiple lesions were excluded from this analysis. There were 405 patients with glioblastoma multiforme; their median age was 46.5 years (range 22 to 70 years). Eighteen (5%) of these patients had multiple CNS lesions, five of which were in the spinal cord. The median time from diagnosis to detection of the second lesion in this group was 59.5 weeks (range 10 to 182 weeks). There were 630 patients with anaplastic glioma (which included mixed malignant glioma and highly anaplastic, gemistocytic, moderately anaplastic, and anaplastic astrocytomas); their median age was 30 years (range 2 to 62 years). Fifty-four (8.6%) of these patients had multiple lesions, 10 of which were in the spinal cord; only one case of extraneural metastasis was found. The median time from diagnosis to detection of the second lesion in this group was 101 weeks (range 14 to 459 weeks). These results show that more than 90% of CNS gliomas recur at the site of the original tumor. Considering the high frequency of intellectual dysfunction after whole-brain radiation therapy, the use of focal radiation fields appears to be the most judicious approach to the treatment of patients with gliomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021931     DOI: 10.3171/jns.1986.65.5.0654

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  54 in total

Review 1.  Combining immunotherapy with radiation for the treatment of glioblastoma.

Authors:  Kevin K H Chow; Wendy Hara; Michael Lim; Gordon Li
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

2.  [Malignant gliomas--radiotherapy].

Authors:  Annemarie Schratter-Sehn
Journal:  Wien Med Wochenschr       Date:  2006-06

3.  The clinical features of spinal leptomeningeal dissemination from malignant gliomas.

Authors:  Jung-Sik Bae; Seung-Ho Yang; Woan-Soo Yoon; Seok-Gu Kang; Yong-Kil Hong; Sin-Soo Jeun
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

4.  [3-Dimensional irradiation planning in brain tumors. The advantages of the method and the clinical results].

Authors:  A L Grosu; H J Feldmann; C Albrecht; P Kneschaurek; R Wehrmann; M W Gross; F B Zimmermann; M Molls
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

5.  PCNA and Ki-67 labelling indices in pre-irradiated and post-irradiated astrocytomas: a comparative immunohistochemical analysis for evaluation of proliferative activity.

Authors:  E Pierce; R Doshi; R Deane
Journal:  Mol Pathol       Date:  1998-04

6.  Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.

Authors:  Marianela Candolfi; James F Curtin; W Stephen Nichols; Akm G Muhammad; Gwendalyn D King; G Elizabeth Pluhar; Elizabeth A McNiel; John R Ohlfest; Andrew B Freese; Peter F Moore; Jonathan Lerner; Pedro R Lowenstein; Maria G Castro
Journal:  J Neurooncol       Date:  2007-09-15       Impact factor: 4.130

7.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

8.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

Review 9.  Spinal canal metastases: a late complication of glioblastoma.

Authors:  M Schwaninger; S Patt; P Henningsen; D Schmidt
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

10.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.